# Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Canonical URL: https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-closing-of-sale-of-rare-pediatric-disease-priority-review-voucher-for-180-million
Ticker: RCKT
Company: Rocket Pharmaceuticals
Source: Rocket Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.rocketpharma.com
## Summary

CRANBURY, N.J. --(BUSINESS WIRE)--Jun. 12, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its

## Article Body
CRANBURY, N.J. --(BUSINESS WIRE)--Jun. 12, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its
## Recent Company News
- 2026-06-25 13:46 EST — [Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-closing-of-sale-of-rare-pediatric-disease-priority-review-voucher-for-180-million) — Source: Rocket Pharmaceuticals
- 2026-06-25 13:46 EST — [Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-06-25 13:46 EST — [Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Rocket Pharmaceuticals
- 2026-06-25 13:46 EST — [Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-kresladitm-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i-lad-i) — Source: Rocket Pharmaceuticals
- 2026-06-25 13:46 EST — [Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)